Our forum is experiencing technical difficulties with comments being displayed. We apologize for the inconvience.

Reply To: NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

GCS Project Home Forum Available Clinical Trials NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Reply To: NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

#4895
Diane Redington
Keymaster

Thank you Heather. Have you or are you participating in any trials? I am looking at a trial with both Nivolumab (Opdivo) and Ipilimumab (Yervoy) with the addition of a new agent called OX40. The idea is that the OX 40 will ramp up the T-cells and the Opdivo and Yervoy will remove the receptors that are blocking the T-cells in the tumor from doing their job.

I hope to start the trial in 2 weeks. If anyone else in participating in a clinical trial, please share your experience.
Diane